Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press83010.17650/1726-9784-2016-15-4-8-17REVIEWSОБЗОРЫ ЛИТЕРАТУРЫTHERAPIES TARGETING CANCER STEM CELLS OF THE TUMOR: THE ONE AND ONLY HOPEТЕРАПИЯ, НАПРАВЛЕННАЯ НА СТВОЛОВУЮ КЛЕТКУ ОПУХОЛИ: НАДЕЖДЫ И ВОЗМОЖНОСТИVartanianA. A.ВартанянАмалия Арташевна
Russian Federation
zhivotov57@mail.ruBaryshnikovK. A.БарышниковК. А.
Russian Federation
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина»3012201615481710042018https://bioterapevt.abvpress.ru/jour/article/view/830

The basic problem in cancer treatment remains the identification of cells responsible for maintaining the whole population of cells in a tumor. For decades it has been considered that all transformed cells within a tumor have carcinogenic potential with unlimited proliferation capacity and metastases formation. At present, the concept of cancer stem cell was introduced indicating that tumor evolves from a small population of long-live and slow proliferating cells. These cells have the capacity to initiate the tumor formation in immunodeficient animals. Among their properties, resistance to standard oncology treatments leads to treatment failure and cancer recurrence. The management and eradication of different types cancer is completely depended on removal of this cell population. Current review presents basic information about cancer stem cell, particularly, the initiation of tumor, the peculiar properties of cancer stem cell, the role of cancer stem cell in metastasis formation and discusses therapeutic strategies targeted cancer stem cell.

Фундаментальной проблемой в лечении рака остается идентификация клеток, способных инициировать и поддерживать рост опухоли. До недавнего времени предполагалось, что все клетки опухоли обладают одинаковой способностью инициировать опухоль и формировать метастазы. Сегодня достоверно показано, что такими свойствами обладает небольшая популяция особых клеток, называемых стволовой клеткой опухоли (СКО). СКО - это специфическая опухолевая клетка, долгоживущая и медленно пролиферирующая, способная при трансплантации иммунодефицитным животным инициировать рост опухоли, идентичной исходной. СКО характеризуются чрезвычайной терапевтической устойчивостью, которая в ответ на лечение только возрастает. Регрессия опухоли и длительная ремиссия после лечения зависят от уничтожения этой самой важной части опухолевых клеток. В обзоре обсуждаются пути возникновения опухоли, характерные особенности СКО, ее роль в метастазировании и терапия, направленная на СКО.

злокачественные новообразованиястволовая клетка опухолимаркеры стволовой клеткитерапия стволовой клетки опухолиcancer stem cellcancer stem cell markerstherapeutic strategies targeted cancer stem cellsGreavis M., Maley C.C. Clonal evolution in cancer. Nature 2012;481(7381):306-13. DOI: 10.1038/nature10762. PMID: 22258609.Eaves C.J. Cancer stem cells: here, there, everywhere? Nature 2008;456(7222):581 -2. DOI: 10.1038/456581a. PMID: 19052611.Osisami M., Keller E.T. Mechanisms of Metastatic Tumor Dormancy. J Clin Med 2013;2(3):136-50. DOI: 10.3390/ jcm2030136. PMID: 26237067.Tomasetti C., Vogelstein B., Parmigiani G. Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation. Proc Natl Acad Sci U S A 2013;110(6):1999-2004. DOI: 10.1073/pnas. 1221068110. PMID: 23345422.Arnold K.M., Opdenaker L.M., Flynn D. et al. Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastasis 2015;8:1-13. DOI: 10.4137/CGM. S11286. PMID: 25674014.Nobel Prize in medicine awarded to Sir John Gurdon and Shinya Yamanaka.www. cnn.com/2012/10/08/world/europe/ sweden-nobel-prize-medicine.Gate D., Danielpour M., Bannykh S. et al. Characterization of cancer stem cells and primary cilia in medulloblastoma. CNS Neurol Disord Drug Targets 2015;14(5):600-11. PMID: 25921740.Epping M.T., Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 2006;99(3):398-403. DOI: 10.1038/sj. bjc. 6604494. PMID: 18648365.Clarke M.F., Dick J.E., Dirks P.B. et al. Cancer stem cells perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66(19):9339-44. DOI: 10.1158/0008- 5472. PMID: 16990346.Gurouard S.D., Murphy G.F. Melanoma stem cell: not rare, but well done. Lab Invest 2010;39:33-49. DOI: 10.1016/j. mam. 2013.10.003. PMID: 24145241.Dragu D.L., Necula L.G., Bleotu C. et al. Therapies targeting cancer stem cells: Current trends and future challenges. World J Stem Cells 2015;7(9):1185-201. DOI: 10.4252/wjsc. v7. i9.1185. PMID: 26516409.Paoletti C., Hayes D.F. Circulating Tumor Cells. Adv Exp Med Biol 2016;882:235-58. DOI: 10.1007/978-3-319 -22909-6. PMID: 26987538.Azevedo A.S., Follain G., Patthabhiraman S. et al. Metastasis of circulating tumor cells: favorable soil or suitable biomechanics, or both? Cell Adh Migr 2015;9(5):345-56. DOI: 10.1080/1933 6918.2015.1059563. PMID: 26312653.Ahn J., Sanz-Moreno V., Marshall C.J. The metastasis gene NEDD9 product acts through integrin ß3 and Src to promote mesenchymal motility and inhibit amoeboid motility. J Cell Sci 2012;125(Pt 7):1814-26. DOI: 10.1242/jcs. 101444. PMID: 22328516.North J.P., Vetto J.T., Murali R. et al. Assessment of copy number status of chromosomes 6 and 11 by FISH provides independent prognostic information in primary melanoma. Am J Surg Pathol 2011;35(8):1146-50. DOI: 10.1097/PAS. 0b013e318222a634. PMID: 21716079.Hoorens I., Vossaert K., Ongenae K. et al. Is early detection of basal cell carcinoma worthwhile? Br J Dermatol 2016;174(6):1258-65. DOI: 10.1111/bjd. 14477. PMID: 26872563.Abdullah L.N., Chow E.K. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013;2(1):3. DOI: 10.1186/2001-1326-2-3. PMID: 23369605.Linton K.J. Structure and function of ABC transporters. Physiology(Bethesda) 2015;43(5):1003-10. DOI: 10.1042/ BST20150132. PMID: 26517915.Frank N.Y., Margaryan A., Huang Y et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65(10):4320-33. DOI: 10.1158/0008- 5472. CAN-04-3327. PMID: 15899824.Januchowski R., Wojtowicz K., Zabel M. The role of aldehyde dehydrogenase(ALDH) in cancer drug resistance. Biomed Pharmacother 2013; 67(7):669-80. DOI: 10.1016/j. biopha. 2013.03.011. PMID: 23602050.Chang L., Graham P., Hao J. et al. Cancer stem cells and signaling pathways in radioresistance. Oncotarget 2016;7(10):11002-17. DOI: 10.18632/ oncotarget. 6760. PMID: 26716904.Skvortsov S., Debbage P., Lukas P. et al. Crosstalk between DNA repair and cancer stem cell(CSC) associated intracellular pathways. Semin Cancer Biol 2015;31:36- DOI: 10.1016/j. semcancer. 2014.06.002. PMID: 24954010.He Y.C., Zhou F.L., Shen Y et al. Apoptotic death of cancer stem cells for cancer therapy. Int J Mol Sci 2014;15(5):8335-51. DOI: 10.3390/ ijms15058335. PMID: 24823879Ojha R., Bhattacharyya S., Singh S.K. Autophagy in Cancer Stem Cells: A Potential Link Between Chemoresistance, Recurrence, and Metastasis. Biores Open Access 2015;4(1):97-108. DOI: 10.1089/ biores. 2014.0035. PMID: 26309786.Wang K., Zhang T., Dong Q. et al. Redox homeostasis: the linchpin in stem cell self-renewal and differentiation. Cell Death Dis 2013;4: e537 - e346. DOI: 10.1038/ cddis. 2013.50. PMID: 23492768.Sato A., Okada M., Shibuya K. et al. Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells. Stem Cell Res 2014;12(1):119-31. PMID: 25473894.Teicher B.A., Fricker S.P. CXCL12(SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010;16:2927- 2931. DOI: 10.1158/1078-0432. CCR-09- 2329. PMID: 20484021.Domanska U.M., Kruizinga R.C., Nagengast W.B. et al. A review on CXCR4/ CXCL12 axis in oncology: No place to hide. Eur J Cancer 2013;49:219-230. DOI: 10.1016/j. ejca. 2012.05.005. PMID: 22683307.Sun Y., Mao X., Fan C. et al. CXCL12-CXCR4 axis promotes the natural selection of breast cancer cell metastasis. Tumour Biol 2014;35:7765-7773. DOI: 10.1007/ s13277-014-1816-1. PMID: 24810923.Orimo A., Gupta P.B., Sgroi D.C. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-348. DOI: PMID: 15882617.Sanchez-Martin L., Sanchez-Mateos P., Cabanas C. CXCR7 impact on CXCL12 biology and disease. Trends Mol Med 2013;19(1):12-22. DOI: 10.1016/j. molmed. 2012.10.004. PMID: 23153575.Welschinger R., Liedtke F., Basnett J. et al. Plerixafor(AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Exp Hematol 2013;41:293-302. DOI: 10.1016/j. exphem. 2012.11.004. PMID: 23178377.Rios A., Hsu S.H., Blanco A. et al. Durable response of glioblastoma to adjuvant therapy consisting of temozolomide and a weekly dose of AMD3100(plerixafor), a CXCR4 inhibitor, together with lapatinib, metformin and niacinamide. Oncoscience 2016; 3(5-6):156-63. DOI: 10.18632/ oncoscience. 311. PMID: 27489862.Drenckhan A., Kurschat N., Dohrmann T. et al. Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer. J Surg Res 2013;182:250-256. DOI: 10.1016/j. jss. 2012.09.035. PMID: 23117118.Wong D., Kandagatla P., Korz W. et al. Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis. BMC Urol 2014;14:12. DOI: 10.1186/1471-2490-14-12. PMID: 24472670.Hoellenriegel J., Zboralski D., Maasch C. et al. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood 2014;123:1032-1039. DOI: 10.1182/ blood-2013-03-493924. PMID: 24277076.Jayson G.C., Kerbel R., Ellis L.M. et al. Antiangiogenic therapy in oncology: current status and future directions. Lancet 2016;388(10043):518-29. DOI: 10.1016/ S0140-6736(15) 01088-0. PMID: 26853587.Baranyi M., Lippai M., Szatmari Z. Role of the stroma in the initiation and progression of tumors. Orv Hetil 2015;156 (45):1816-23. DOI: 10.1556/650. 2015.30294. PMID: 26522855.Schwanbeck R., Martini S., Bernoth K. et al. The Notch signalling pathway: molecular basis of cell content dependency. Eur J Cell Biol 2011;90(6-7):572-581. DOI: 10.1016/j. ejcb. 2010.10.004. PMID: 21126799.Koch U., Radtke F. Notch signaling in solid tumor. Curr Top Dev Biol 2010;92:367-409. DOI: 10.1016/S0070- 2153(10) 92013-9. PMID: 20816403.Vartanian A., Gatsina G., Grigorieva I. et al. The involvement of Notch signaling in melanoma vasculogenic mimicry. Clin Exp Med 2013;13(3):201-9. DOI: 10.1007/ s10238-012-0190-9, PMID: 22627943.Fan X. y-Secretase inhibitor-resistant glioblastoma stem cells require RBPJ to propagate. J Clin Invest 2016;126(7):2415-8. DOI: 10.1172/ JCI88619. PMID: 27322058.Yen W.C., Fischer M.M., Axelrod F. et al. Targeting Notch signaling with a Notch2/Notch3 antagonist(tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res 2015;21:2084-2095. DOI: 10.1158/1078- 0432. PMID: 25934888.Cohen D.J. Targeting the hedgehog pathway: role in cancer and clinical implications of its inhibition. Hematol Oncol Clin North Am 2012;26:565-588. DOI: 10.1016/j. hoc. 2012.01.005. PMID: 22520980.Merchant A.A., Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010;16:3130-3140. DOI: 10.1158/1078-0432. CCR-09-2846. PMID: 20530699.Chen J.K. I only have eye for ewe: the discovery of cyclopamine and development of Hedgehog pathway-targeting drugs. Nat Prod Rep 2016;33(5):595-601. DOI: 10.1039/ c5np00153f. PMID: 26787175.Yang T. and Rycaj K. Targeted therapy against cancer stem cells. Oncol Lett 2015;10:27-33. PMID: 26170972.Wend P., Holland J.D., Ziebold U. et al. Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol 2010;21:855-863. DOI: 10.1016/j. semcdb. 2010.09.004. PMID: 20837152.Yang K., Wang X., Zhang H. et al. The evolving roles of canonical WNT signaling in stem cells and tumorigenesis: implications in targeted cancer therapies. Lab Invest 2016;96(2):116-36. DOI: 10.1038/labinvest. 2015.144. PMID: 26618721.Le P.N., McDermott J. D., Jimeno A. Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28. Pharmacol Ther 2015;146:1-11. DOI: 10.1016 j.pharmthera. 2014.08.005. PMID: 25172549.Abdullah L.N., Chow E.K. Mechanisms of chemoresistance in cancer stem cells. Clin Transl Med 2013;17:3-14. DOI: 10.1186/2001-1326-2-3. PMID: 23369605.Minderman H., O’Loughlin K.L., Pendyala L. et al. VX-710(biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 2004;10:1826-1834. PMID: 15014037.Kuhlmann J.D., Hein L., Kurth I. et al. Targeting Cancer Stem Cells: Promises and Challenges. Anticancer Agents Med Chem 2016;16(1):38-58. PMID: 26179271.Liang Y., Li S., Chen L. The physiological role of drug transporters. Protein Cell 2015;6(5):334-50. DOI: 10.1007/s13238-015-0148-2. PMID: 25797421.Fukuda S., Pelus L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5(5):1087-98. PMID: 16731740.Plasilova M., Zivny J., Jelinek J. et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 2002;16:67-73. PMID: 11840265.Unterkircher T., Cristofanon S., Vellanki S.H. et al. Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis. Clin Cancer Res 2011;17:4019-4030. DOI: 10.1158/1078-0432. CCR-11-0075. PMID: 21525171.Yin S., Xu L., Bandyopadhyay S. et al. Cisplatin and TRAIL enhance breast cancer stem cell death. Int J Oncol 2011;39:891- 898. DOI: 10.3892/ijo. 2011.1085. PMID: 21687939.Zhou J., Zhang H., Gu P. et al. NFkappaB pathway inhibitors preferentially inhibit breast cancer stemlike cells. Breast Cancer Res Treat 2008;111:419-427. PMID: 17965935.Campos B., Wan F., Farhadi M. et al. Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin Cancer Res 2010;16:2715-2728. DOI: 10.1158/1078-0432. CCR-09-1800. PMID: 20442299.Ginestier C., Wicinski J., Cervera N. et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 2009;8:3297-3302. PMID: 19806016.Salvador M.A., Wicinski J., Cabaud O. et al. The histone deacetylase inhibitor abexinostat induces cancer stem cells differentiation in breast cancer with low Xist expression. Clin Cancer Res 2013;19:6520- 6531. DOI: 10.1158/1078-0432. CCR-13- 0877. PMID: 24141629.Dong Y., Han Q., Zou Y. et al. Longterm exposure to imatinib reduced cancer stem cell ability through induction of cell differentiation via activation of MAPK signaling in glioblastoma cells. Mol Cell Biochem 2012;370:89-102. DOI: 10.1007/s11010-012-1401-0.